Technology Investment Scrutiny Rises
A US proposal to bar certain investments in Chinese biotechnology firms, alongside export restrictions and semiconductor-company pullbacks, signals rising scrutiny of cross-border technology capital. Investors face greater regulatory exposure and should reassess diligence, market access and exit assumptions.
Supply Chain Diversification Imperative
Companies are treating India as an additional production node rather than a wholesale China replacement, while India seeks inputs and capabilities from Japan, South Korea and Taiwan. This portfolio approach improves optionality but requires deeper local supplier development and capacity.
Farm Purchases as Trade Leverage
US officials are pressing Beijing to meet agricultural purchase commitments, including soybean orders, and report delays in some deliveries. Compliance disputes could put export revenues and commodity flows at risk, while tying farm trade to broader tariff negotiations.
Hormuz Energy Supply Vulnerability
Conflict around the Strait of Hormuz has heightened exposure for Indian energy buyers: roughly 40% of oil imports and 60% of LNG imports previously transited the route. Higher freight, insurance and crude costs can feed inflation and widen import bills.
Unstable US Tariff Exposure
Indian exporters face a shifting US tariff regime: sources cite a 10% Section 301 duty, continuing investigations and possible sectoral measures affecting pharmaceuticals and electronics. Unpredictable landed costs threaten margins, order pricing and capacity planning, particularly for smaller exporters.
Joint Defence Production Expansion
The EU plans to direct up to €1 billion toward joint Ukrainian-European defence production, while Ukraine and Finland signed projects worth about €300 million for drones, robotics and weapons. Partnerships offer market opportunities but require execution amid wartime risks.